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1ABSTRACT
Radioprotective Effects of Recombinant Human Epidermal Growth 
Factor (rhEGF) in C3H/HeJ mice
Haejin OH
Department of Medical Science
The Graduate School, Yonsei University 
(Directed by Professor Jinsil Seong)
Object 
  In order to investigate radioprotective effects of recombinant human 
epidermal growth factor (rhEGF) on radiation-induced mucosal damage in 
C3H/HeJ mice. 
 
Materials and Methods 
  The radiation damage model was established that C3H/HeJ mice 
exposed to a single dose whole body irradiation of 8 Gy, 10 Gy. The 
groups of treatment model were divided into 4 groups: control, 10 Gy 
irradiation alone group, rhEGFalone group, and combination group of 
rhEGF and radiation. The rhEGF was administered 100 ㎍/㎏ 
intraperitoneally on day 1, 2, 3 and 3.5. Histologic examination was 
performed with H&E stain in jejunal mucosa. Radiation-induced apoptosis 
2was determined in each group with the Apoptag kit: DNA terminal 
transferase nick-end labeling method. Tissue sections were evaluated for 
PCNA expression by immunohistochemical stain. 
Results 
  In the radiation damage model, the 8 Gy irradiated groups statistically 
had less weight loss compared to the 10 Gy irradiated group. The 
number of crypt cells was greatly decreased at 24h after 10 Gy in 
jejunum crypt by H&E stain. Apoptosis index of jejunum crypt in 10 Gy 
irradiated group was significantly increased at 24h after 
irradiation(p<0.05). In the treatment model, the combination group showed 
significantly improvement the reduction of weight loss and the number of 
radiation-induced apoptosis compared with 10 Gy irradiated group.
Conclusion 
  It is suggested that rhEGF represents an effective strategy to reduce small 
intestine mucosal injury of radiation treatment in murine models. By promoting 
mucosal repair and protecting mucosal layer, rhEGF decreased 
radiation-induced apoptosis. In conclusion, rhEGF administered treatment 
decrease apoptosis of small intestine mucosal after the radiation exposure.

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I. IN TROD U CTION
  Radiotherapy is one of the major treatment modalities for cancer. In 
Asia including Korea, gastrointestinal (GI) cancer is a major malignancy. 
However high radiosensitivities of GI organs proposes a major limitation 
in applying radiotherapy in GI cancers1-3.
As a result of ionizing radiation, acute morphological changes of the 
intestine are observed within 24-48 hr. The villi gradually shorten in 
length and the total thickness of the mucosa is reduced. Consequently, 
malaborption of nutrients occurs and water and electrolyte transport can 
be markedly inhibited. These changes result in loss of fluid leading to 
dehydration, electrolyte depletion, and death4-6.
The mechanisms underlying the effect of radiation on small intestine 
4have been reported apoptosis and necrosis have been identified as two 
main forms of cell death after radiation. However, mucosal injury has 
been mainly attributed to apoptosis of epithelial cells as evidenced by 
mouse model of GI syndrome following whole body irradiation7,8.
The effects of recombinant growth hormone (rhGF) on intestine 
mucosal are not well defined. A variety of approaches using growth 
factor has been performed in preclinical model for the efficacy in 
alleviating radiation-induced mucosal injury. Keratinocyte growth factor 
(KGF) induces a variety of responses in epithelia, which involves 
stimulation of epithelial proliferation, modification of migration and 
differentiation processes. KGF plays a key role in wound healing, with a 
substantial increase in dermal transcription activity. Topical application has 
stimulated wound healing in animal models9,10. 
Epidermal growth factor (EGF) constitutes a polypeptide hormone 
that binds specifically to the epidermal growth factor receptor (EGFR) 
located ubiquitously in epithelial cells of the gastrointestinal tract as well 
as in other organs and tissues. The ligand-receptor interaction between 
EGF and EGFR results in intestinal cell migration and proliferation to 
repair and restore mucosal continuity11,12. The EGF is present in relevant 
concentrations in the saliva, in other biological fluids, and in the milk 
from bresat-feeding mothers, which can reach about 300 times the normal 
serum concentration13,14. 
The EGF produced by a recombinant technique is an analogue to 
5the natural or recombinant growth factor EGF with smilar cell 
proliferation propertis.    
    EGF plays a critical role in wound repair and healing. EGF has also 
been reported to have a mucoprotective potential15-18. Olsen, et al 
reported that the EGF receptor and EGF producing cells increase around 
gastric ulcer in rats19. Girdler, et al reported that EGF administration 
regulated the healing of ulcers in rats and humans20,21. In 
radiation-induced oral mucosal injury model, EGF has been shown to 
enhance the recovery22. These results suggest that EGF might play an 
import role in repair of small intestinal mucosal injury by radiation.
The purpose of the study was to investigate the radioprotective effect 
of rhEGF on radiation induced intestinal mucosal damage.
6II. MA TERIA LS A N D  METHOD S
1. Animals
  The study has been reviewed and approved by the committee that 
oversees the ethics of research involving the use of animals and the 
welfare of the animals. The study involved 8-10 week old male C3H/HeJ 
mice that were bred in our specific pathogen-free mouse colony in the 
Division of Laboratory Animal Medicine, college of Medicine, Yonsei 
University. The temperature (22 ℃ ) and humidity (55%) were controlled 
constantly. The water (RO water) and diet (PMI) were supplied ad 
libitum. The care and use of laboratory animals in these experiments 
were based on the Guidelines and Regulations for Use and Care of 
Animals in Yonsei University.
2. Radiation and rhEGF administration
 To establish a model of radiation-induced intestinal injury, C3H/HeJ 
mice were given two different radiation doses in their whole bodies: a 
single dose of 8 Gy or 10 Gy using clinical linear accelerator (Varian 
Co. Milpitas, CA, USA).
 Using this mouse model, therapeutic effect of rhEGF was tested on 
radiation-induced intestinal injury. The mouse model was injected with 
rhEGF (100 ㎍/kg/day) i.p. on days 1 to 4 after 10 Gy irradiation. 
Recombinant human epidermal growth factor (rhEGF) (Daewoong 
7Pharmeceutic Co., Seoul, Republic of Korea) was administered i.p. on 
radiation-treated mice.
 The mice were divided into four groups: control, radiation alone, rhEGF 
alone, and radiation plus rhEGF (combination group). In each group 10 
mice were allocated. Control group received no RT. Radiation alone 
group received a single dose of radiation on their whole bodies. 
Combination group received a single dose of radiation plus rhEGF (100 
㎍/kg/day).
3. Analysis of body weight
  Mice were weighted daily to determine changes in body weight over 
time. Mice were monitored closely for any sign of morbidity during the 
experiments. 
4. Crypt survival
  
  Intestinal damage was assessed using the jejunal microcolony assay of 
Withers and Elkind23,24. For the jejunal microcolony assay, mice were 
sacrificed 1 to 7 days after irradiation, and 2.5 cm segments of jejunum 
were removed and fixed in neutral buffered formalin. After embedding in 
paraffin, 4 ㎛ transverse sections were cut and stained with hematoxylin 
and eosin (H&E). The numbers of surviving crypts per transverse 
8histological section were counted using the criterion of at least 10 
surviving cells as indicative of a surviving crypt. Crypts in five to eight 
circumferences per mouse were counted and averaged. Data were reported 
as mean ± SE.
5. Assessment of proliferating nuclear antigene (PCNA) expression and 
apoptosis index (A.I.)
The small intestine tissue was analyzed for morphological changes. 
Immunohistochemical stain was performed according to the method 
previously described using antibodies targeting proliferating cells nuclear 
antigen (PCNA) (PC 10; Dako A/S, Glostrup, Denmark)25,26. Antibodies 
were used at the dilution recommended by the manufacturer. PCNA count 
was scored on coded slides at 400X magnification. And then, ten fields 
of non-necrotic areas were selected randomly across each jejunum section 
and in each field proliferating cells were expressed as a percentage of 
1000 nuclei. The number and position of labeled cells in the crypts of 
the small intestine were recorded. Only strongly labeled cells were 
counted. The proliferation count calculated as 100 times the number of 
labeled cells per crypt. 
Assessment of apoptosis was performed according to the method 
previously described27. In brief, tumor samples were collected and 
apoptosis was assessed in tissue sections. The tumors were immediately 
9excised and placed in neutral buffered formalin. The tissues were 
embedded in paraffin blocks and 4 ㎛ sections were cut and stained with 
the Apoptag staining kit (Chemicone, Temecula, CA, USA). Apoptotic 
cells were scored on coded slides at 400X magnification according to the 
terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end 
labeling method. TUNEL-positive cells were considered apoptotic only 
when associated with apoptotic morphology as previously described and 
illustrated28. Ten fields of non-necrotic areas were selected randomly 
across each jejunum section and in each field apoptotic bodies were 
expressed as a percentage of 1000 nuclei. Statistical significance was 
assessed using Student’s t test (p<0.05).
6. Treatment and tumor growth delay analysis
For tumor growth delay analysis, 4 experimental groups were set: 
control group, radiation alone group, rhEGF alone group, and radiation 
plus rhEGF group. In each group 10 mice were allocated. rhEGF was 
obtained from Daewoong Pharmeceutic Co (Seoul, Republic of Korea). 
The radiation alone group was irradiated when the tumors grew to a 
mean 7.5-8 mm in diameter. The tumor-bearing legs were treated with a 
single dose of 25 Gy using a linear accelerator (Varian Co., Milpitas, 
CA, USA). The drug alone group was given 100 ㎍/kg once daily 
intraperitoneally for 4 days when the tumors had grown to a mean 7.5-8 
10
mm in diameter29. For the combination group, radiation administrated 
following the above method. The described therapies were combined to 
treat the radiation plus rhEGF group. Tumors were measured regularly for 
tumor growth delay after treatment. The effect of radiation on tumor 
growth was determined by measuring three orthogonal tumor diameters 
with calipers at 2-day intervals until the tumors grew to at least 12 mm 
in diameter. The effect of the treatment on tumor growth delay (AGD) 
was defined as the time in days for the tumors to reach 12 mm in the 
treated group minus the mean time to reach 12 mm in the untreated 
control group. 
The enhancement factor of tumor radioresponse was obtained by 
dividing normalized tumor growth delay (NGD) with AGD caused by 
radiation. The NGD was defined as the time in days for tumors to reach 
12 mm in mice treated by the combination treatment minus the time in 
days for tumors to reach 12 mm in the treated group by rhEGF only. 
Animals were closely observed for any occurrence of toxicity until the 
last observation day.
7. Statistical analysis
All values were expressed as mean ± SE. Statistical analysis was 
11
performed by analysis of variance and the t-test. P-value of less than 
0.05 indicated statistical significance
12
III. RESU LTS
1. Radiation-induced small intestinal injury
 1.1 Survival rate and change of body weight
    All mice survived until day 4. In 10 Gy group however, one mouse 
died on day 5 and two mice died on day 7, yielding 11-day survival 
rate of 87.8 %. In 8 Gy group, two mice died on day 11, yielding 
11-day survival rate of 90.5 % (Fig.1). 
Fig.1. Survival rate after whole body radiation in C3H/HeJ mice. Values 
are expressed as means ± SE.
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    Also, 8 Gy and 10 Gy groups showed statistically significant 
difference in body weight after whole body irradiation (p<0.05) 8 Gy 
group revealed weight gain until day 2, and then began to show sudden 
decrease at day 6. On the other hand, 10 Gy group showed considerable 
weight loss until day 7 (Fig.2).
Fig.2. Change in body weight after whole body radiation. Body weight 
was measured every 24 hours for 11 days (control; n=5~7, 8 Gy group; 
n=20~25, 10 Gy group; n=20~25). In 8 Gy irradiated group, mice body 
weight tended to decrease starting on day 6. But 10 Gy irradiated group, 
mice body weight started significant decrease on Day 3. Values are 
expressed as means ±SE: *p<0.05 compared control to 10 Gy and 8 Gy 
group.
14
 1.2 Number of crypt per circumference
 In 8 Gy and 10 Gy group, crypts survival began to decrease on day 
1. However in 8 Gy group, crypts survival increased continuously. On 
the other hand crypts survival decreased until day 3 and then increased 
until day 7 in 10 Gy group. As a result, the number of crypts per 
circumference was significant less in 10 Gy group than in 8 Gy group 
(Fig.3) (p<0.05).
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Fig.3. Number of crypt per circumference(mm2). Jejunal crypt count after 
8 Gy (♦) and 10 Gy (■ ) whole body radiation. Samples of the proximal 
jejunum were fixed in formaldehyde, and were embedded in paraffin 
blocks. Transverse tissue sections of the full jejunal circumference (4 ㎛
thick) were stained with H&E and scored for the number of regenerative 
crypts. Crypts in five to eight circumferences per mouse were counted 
and averaged. Vertical bars are standard deviation of mean. *p<0.05 
compared control to 10 Gy and 8 Gy group.
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1.3 Apoptosis index (A.I.) in irradiated jejunum crypt
 The apoptosis index was determined in the sections of the small 
intestine jejunum. The effect of dose was detected the segments of the 
intestine in mice (Fig.4). 
  In 8 Gy and 10 Gy groups, A.I. began to increase on day 1, but 
then decreased gradually day 7. Also, apoptosis dramatically increased in 
10 Gy group compared with 8 Gy group. Higher than 6 fold apoptosis 
was shown in 10 Gy group compared with in 8 Gy group.
17
Fig.4. Apoptosis index (A.I.) in irradiated jejunum crypt. Apoptosis cells 
detected by TUNEL assay show at control, 1,2,3,3.5,5 and 7 days after 8 
Gy group (A) and 10 Gy group (B) whole body irradiation in crypt of 
C3H/HeJ mice. The apoptosis index is the number of apoptosis body per 
1,000 nuclei. Vertical bars are standard deviation of mean. *p<0.05 
compared control to 10 Gy and 8 Gy group.
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2. Therapeutic effect of rhEGF on radiation-induced small intestinal 
injury 
  2.1 Change of body weight
    In 10 Gy group, body weight began to decrease from day 1. In 10 
Gy plus rhEGF (combination group) body weight decreased from day 1 
and started to recover from day 3. The difference in body weight 
between the 10 Gy and combination group was statistically significant 
(p<0.05). In addition, combination group showed weight gain compared 
with 10 Gy group beginning on day 1, whereas 10 Gy group mice 
showed significant decrease of body weight until day 7 (Fig. 5).
19
Fig.5. Effect of EGF on mouse body weight. Change of body weight 
was measured every 24 hours for 7 days. Change of body weight gain 
after control, treatment of radiation only, rhEGF only, or combination 
(rhEGF plus radiation) in C3H/HeJ mice. In 10 Gy irradiated group, 
mouse body weight tended to decrease starting on day 3, but 
combination group lost significantly less weight than mouse not treated 
with rhEGF. *p<0.05 compared control to radiation alone and 
combination group. Values are expressed as means ±SE.
20
 2.2 A.I. and PCNA ratio in irradiated jejunum crypt 
    The level of apoptosis and PCNA was observed in days 5 and 7. 
On day 5, the A.I. and PCNA ratio significantly decreased in 
combination group compared with 10 Gy group (p<0.05) (Fig.6). Because 
A.I. decreased in combination group compared with 10 Gy group (Fig.6). 
These data suggest that rhEGF could suppress apoptosis and accelerate 
proliferation in radiation induced jejunal crypt injury of C3H/HeJ mice.
Fig.6. A.I. and PCNA ratio in irradiated jejunum crypt. The apoptosis 
cells detected by TUNEL assay and PCNA index. Apoptosis showed at 
control, 5 and 7 days after 10 Gy whole body irradiation in crypt of 
C3H/HeJ mice. The apoptosis index is the number of apoptosis body per 
1,000 nuclei. *p<0.05 compared radiation alone and combination group. 
Vertical bars are standard deviation of mean.
21
 2.3 Histology
  To evaluate the effect of rhEGF on irradiated jejunal mucosa, the 
histological samples of small intestine mucosa was examined on days 3.5 
and 7. Histological findings of jejunal mucosa on day 3.5 revealed 
difference between the radiation alone group and combination group 
(Fig.7. B. C). The most obvious changes in intestinal histology induced 
by radiation were an increase in the number of apoptotic bodies, 
destruction of crypt cells, necrosis of gastrointestinal epithelium and 
architectural changes consisting of shortening of villi as compared to 
rhEGF treated mice (Fig.7. B. C). 
 Also, the villous height decreased after irradiation. Radiation damage 
was maximal on day 3 but treatment with rhEGF showed decrease in the 
number of apoptotic bodies and increase in the number of PCNA. 
Moreover, villous height increased and repaired villi were observed in 
combination group compared with radiation alone group. However, there 
was no difference between the radiation alone group and combination 
group on day 7 (data not shown). 
 Our results suggest that rhEGF treatment resulted in preservation of 
villi, attenuation of crypt apoptosis, and enhancement of crypt 
proliferation.
22
(A)                 (B)                    (C)
Fig.7. Histopathology in jejunum after 10 Gy whole body radiation on 
Day 3.5 (H&E, X100). (A) Villous architecture is normal. Positive cells 
are noted in the full length of villi. (B) Section showing jejunum 3.5 
days after 10 Gy radiation.  (C) Note that the healed mucosa of mice 
treated with 100 ㎍ /kg/day rhEGF. Crypts and villi are little damaged.
23
3. Tumor growth delay in rhEGF treated group
  To test whether rhEGF might enhance tumor growth, tumor growth 
delay assay was done using murine syngeneic tumors; a radioresistant 
tumor, HCa-I hepatocarcinoma, (TCD 50 ≥ 80 Gy), a radiosensitive 
tumor, MCa-K mammary carcinoma (TCD 50 ≥ 42.9 Gy)30.
 In HCa-I, the time for tumor growth from 8 to 12 mm was 11.6 days 
and 8.8 days in the radiation alone and the rhEGF alone group, 
respectively, which corresponds with an AGD of 2 days (rhEGF alone) 
and 4.8 days (radiation alone). When radiation was combined with 
rhEGF, the time for growth from 8 to 12 mm was 11.6 days and the 
NGD was 2.8 days. An enhancement factor was calculated as 0.6 
(Fig.8.A).
 In MCa-K, the time for tumor growth from 8 to 12 mm was 11.5 
days and 9.2 days in the radiation alone and the rhEGF alone group, 
respectively, which corresponds with an AGD of 1.6 days (rhEGF alone) 
and 3.9 days (radiation alone). When radiation was combined with 
rhEGF, the time for growth from 8 to 12 mm was 11.6 days and the 
NGD was 3.2 days. An enhancement factor was calculated as 0.8 
(Fig.8.B).
  These data suggest that rhEGF did not affect the antitumor effect of 
radiation.
24
(A)
(B)
Fig.8. Tumor growth delay assay of HCa-I (A) and MCa-K (B). Tumor 
growth delay assay of HCa-I (A) treated with radiation (▲ , rhEGF (■ ), 
combination (rhEGF plus radiation) (*) or control (♦ and and MCa-K 
(B) treated with radiation (*), rhEGF (▲ , combination 
(rhEGF+radiation) (+) or control (♦. rhEGF did not affect the antitumor 
effect of radiation with an enhancement factor (E.F.) of 0.6 in HCa-I and 
0.8 in MCa-K .
25
IV . D ISCU SSION
Epidermal growth factor (EGF), a ~6-kDa polypeptide, induces cell 
proliferation, differentiation, migration. EGF is present in various body 
fluids and tissues, and is continuously secreted into the gastrointestinal 
lumen in humans by submandibular glands, mucous neck cells of the 
stomach, Brunner’s glands of the duodenum, Paneth cells of the small 
intestine, and ulcer-associated cell lineage (a recently identified glandular 
structure induced at the site of injury). Especially, EGF and EGF family 
of related peptides are involved as key components in the maintenance 
and repair of mucosa. EGF binds to both low and high affinities sites on 
cells expressing the EGF receptor (EGFR). Ligand binding to the EGFR 
activates RTK activity leading to DNA synthesis and cell growth31-32.
Potten, et al. has described the sequence of events after whole body 
exposure to radiation; at doses <15 Gy, surviving progenitors, albeit even 
a single surviving clonogen per crypt, lead to crypt recovery, identified 
by 3.5 days after irradiation as typical regenerative crypts. Also at doses 
≥15 Gy, extensive depletion of crypt-villus units leads to mucosal 
denudation and animal death from the GI syndrome33-35. Therefore 8 and 
10 Gy doses were tested for establishing radiation-induced intestinal 
mucosal damage model. In this study 10 Gy model was shown to be 
suitable since the severity of damage and its repair was dose dependent 
more obvious in 10 Gy compared to 8 Gy model.
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In our 10 Gy model, mucosal damage was maximal on day 2 and 
started to recover from day 3.5, approaching to the control level on day 
5 (Fig.3,4).
Several molecules have been tested and reported for alleviating 
mucosal damage by radiation. KGF has been reported for promising 
results in preventing the incidence of oral mucosal injury before 
irradiation36. rhEGF has shown suitable results in improving high 
incidence of oral mucositis37.
In this study, systemic rhEGF administration alleviated loss of body 
weight and this effect seemed to be due to recovery of mucosal injury 
after radiation (Fig.5,7). We observed rhEGF to be associated with 
morphologic changes. In radiation alone group, on Day 3.5, crypts were 
diminished and villi lengths were shorten. However, rhEGF treated mice 
mucosa showed relatively higher level both in the number of crypt cells 
and the height of the villi after radiation.
Apoptosis index (A.I.) significantly decreased and PCNA index (P.I) 
significantly increased in combination group compared with radiation 
alone group on Day 5 (Fig.6). This result suggests that rhEGF protects 
the mucosa from radiation-induced apoptosis and accelerates proliferation, 
showing the possibility of rhEGF as a mucoprotectant.
We also tested a higher dose (200 ㎍/kg) of rhEGF to test if 
radiation injured mucosa showed dose dependent responses to rhEGF.  
From 50 to 100 ㎍/kg, the response was dose dependent but no 
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additional effect at dose of 200 ㎍/kg (data not shown).
In systemic administrated GFs, there might be a concern that it could 
either stimulate tumor growth in vivo or protect the tumor cells from 
radiotherapy38. The two tumors tested in this study involve a 
radioresistant one (HCa-I) and a radiosensitive one (MCa-K).(33-34) In 
this study, systemic rhEGF treatment did not enhance tumor growth in 
vivo. Showing that systemic rhEGF is protective of epithelia without 
enhancement of tumor growth.
  In conclusion, it is suggested that rhEGF represents an effective 
strategy to reduce small intestine mucosal side effects of radiation 
treatment in murine model. By promoting mucosal repair and protecting 
mucosal layer, rhEGF can ameliorate intestinal mucosal injury and clinical 
signs such as loss of body weight. 
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V . CON CLU SION
It is suggested that rhEGF represents an effective strategy to reduce small 
intestine mucosal injury of radiation treatment in murine models. By promoting 
mucosal repair and protecting mucosal layer, rhEGF decreased 
radiation-induced apoptosis. 
     In conclusion, rhEGF administered treatment decrease apoptosis of small 
intestine mucosal after the radiation exposure.
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ABSTRACT (IN KOREAN)
RecombinanthumanRpidermalGrowthFactor(rhEGF)의방사선보호작용에 대한 실험적 연구
<지도교수 성 진 실>
연세대학교 대학원 의과학과
오 해 진
목 적: 본 연구에서는 방사선이 조사된 C3H/HeJ마우스에서 재조합표피성장인자(rhEGF)가 방사선에 의한 점막의손상의 보호에 관여하는지를 알아보고자 하였다.
대상 및 방법: 마우스 손상 모델은 C3H/HeJ마우스에 전신방사선조사 (8,10Gy)하여 성립하였다.실험군은 정상대조군,10 Gy 방사선 단독그룹,rhEGF 단독투여그룹,방사선조사와rhEGF 투여병행군으로 각각 구분하였다. rhEGF의 투여는1,2,3과 3.5일에 100㎍/kg의 용량을 사용하여 복강에 주사 하였다.소장점막의 병리 조직학적 검사를 위하여 H&E염색을 시행하였다.방사선에 의해 유도되는 세포고사는 DNA terminaltransferasenick-endlabelingassay방법으로 Apoptatagkit를사용하여 시행하였다.PCNA 발현정도를 면역조직화학염색을통해 측정하였다.
결과: 마우스 손상모델에서,8Gy이 10Gy그룹보다 마우스의 체중이 덜 감소하였다.H&E염색에서 10Gy방사선 투여군의 소낭선세포가 24시간부터 감소하였다. Apoptosisindex는10Gy방사선 단독투여군에서 방사선 조사 후 24시간째 의의있
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게 증가되었다(p<0.05).방사선조사와 rhEGF투여병행군에서는10Gy방사선 단독그룹에 비하여 방사선의 의한 세포고사가 감소하였고,마우스의 체중 감소가 향상됨을 관찰 할 수 있었다.
결론:마우스 모델에서 rhEGF는 방사선 조사 후 소장의 점막손상을 효과적으로 회복시켰다.점막의 회복을 촉진시키고,점막을 보호하는 기전에 의하여 rhEGF는 방사선에 의한 세포고사를 감소시킨다.결과적으로 rhEGF의 처치는 방사선조사 후의마우스 소장 점막의 세포고사를 감소시켰다.
핵심용어 :방사선 , 소장 , 손상 , 재조합표피성장인자 , 세포고사
